Caplin, Martyn E <br/><br/>
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.  [electronic resource] 

 -  Endocrine-related cancer  Mar 2016 
 - 191-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1479-6821 
<br/><br/><label>Standard No.: </label>10.1530/ERC-15-0490  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Disease-Free Survival<br/>Humans<br/>Intestinal Neoplasms--drug therapy<br/>Neuroendocrine Tumors--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Peptides, Cyclic--adverse effects<br/>Somatostatin--adverse effects<br/>Treatment Outcome